March 10, 2020 / 6:24 AM / a month ago

BRIEF-Innate Pharma FY Net Result Turns To Loss Of 20.8 Million Euros

March 10 (Reuters) - Innate Pharma SA:

* INNATE PHARMA REPORTS FULL YEAR 2019 FINANCIAL RESULTS AND BUSINESS UPDATE

* MONALIZUMAB EXPANSION COHORTS IN IO-PRETREATED AND IO-NAÏVE PATIENTS ARE ON TRACK TO DELIVER PRELIMINARY DATA IN 2020

* CASH POSITION OF €255.9 MILLION AS OF DECEMBER 31, 2019

* REVENUE AND OTHER INCOME AMOUNTED TO EUR 85.8M IN 2019 (2018: EUR 94.0M)

* FY NET LOSS OF EUR 20.8 MILLION VERSUS PROFIT OF EUR 3.0 MILLION YEAR AGO

* FY OPERATING LOSS OF EUR 27.1 MILLION VERSUS PROFIT OF EUR 5.1 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below